Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

被引：0
|
作者：
Igor Bondarenko
Oleg A Gladkov
Reiner Elsaesser
Anton Buchner
Peter Bias
机构：
[1] State Medical Academy,Dnipropetrovsk
[2] Chelyabinsk Regional Clinical Oncology Center,undefined
[3] Teva Ratiopharm,undefined
来源：
BMC Cancer | / 13卷
关键词：
Neutropenia; Febrile neutropenia; Breast cancer; Recombinant granulocyte-colony stimulating factor; Lipegfilgrastim; Pegfilgrastim;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second Phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial)
    Schwartzberg, L.
    Bhat, G.
    Mezei, K.
    Lang, I.
    Moon, Y. W.
    Senviratne, L.
    Chawla, S.
    Cobb, P.
    Yang, Z.
    CANCER RESEARCH, 2019, 79 (04)
  • [32] Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
    Miller, KD
    McCaskill-Stevens, W
    Sisk, J
    Loesch, DM
    Monaco, F
    Seshadri, R
    Sledge, GW
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3033 - 3037
  • [33] A phase III randomized trial of doxorubicin (A) and docetaxel (D) versus doxorubicin and paclitaxel (P) in metastatic breast cancer - preliminary results of the Erasme 3 study
    Cassier, PA
    Chabaud, S
    Freyer, G
    Peaud, PY
    Tigaud, JD
    Cure, H
    Ofeuvre, H
    Salles, B
    Martin, C
    Jacquin, JP
    Agostini, C
    Bachelot, T
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S279 - S279
  • [34] The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial
    Zhao, Qun
    Lian, Changhong
    Huo, Zhibin
    Li, Ming
    Liu, Yang
    Fan, Liqiao
    Tan, Bibo
    Zhao, Xuefeng
    Zhang, Zhidong
    Wang, Dong
    Liu, Yu
    Guo, Honghai
    Yang, Peigang
    Tian, Yuan
    Li, Yong
    CANCER MEDICINE, 2020, 9 (16): : 5731 - 5745
  • [35] Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial).
    Schwartzberg, Lee Steven
    Yang, Zandong
    Peguero, Julio Antonio
    Agajanian, Richy
    Bharadwaj, Jayaram S.
    Restrepo, Alvaro
    Hlalah, Osama
    Mehmi, Inderjit
    Bhat, Gajanan
    Cobb, Patrick Wayne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer:: A randomized phase II trial
    Schneeweiss, Andreas
    Lauschner, Ilka
    Ruiz, Amparo
    Guerrero, Angel
    Sanchez-Rovira, Pedro
    Segui, Miguel Angel
    Goerke, Kay
    Wolf, Michael
    Manikhas, Alexey G.
    Wacker, Juergen
    Marme, Frederik
    Lichter, Peter
    Sinn, Hans-Peter
    Sohn, Christof
    Mansouri, Kambiz
    Bauknecht, Thomas
    Hahn, Meinhard
    CLINICAL BREAST CANCER, 2007, 7 (07) : 555 - 558
  • [37] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [38] Safety and efficacy of tow-dose pegfilgrastim (pegfil) in maintaining chemotherapy (CT) dose density in patients (pts) receiving docetaxel/doxorubicin/cyclophosphamide (TAC) or doxorubicin/cyclophosphamide (AC) as neoadjuvant chemotherapy (NCT) for stage II-III breast cancer (BC)
    Kim, E.
    Jin, R.
    Choi, K.
    Frankel, P. H.
    Somlo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy
    Anton Buchner
    Reiner Elsässer
    Peter Bias
    Breast Cancer Research and Treatment, 2014, 148 : 107 - 116
  • [40] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer:: results of the ERASME 3 study
    Cassier, Philippe A.
    Chabaud, Sylvie
    Trillet-Lenoir, Veronique
    Peaud, Pierre-Yves
    Tigaud, Jean-Dominique
    Cure, Herve
    Orfeuvre, Hubert
    Salles, Bruno
    Martin, Claude
    Jacquin, Jean-Philippe
    Agostini, Cecile
    Guastalla, Jean-Paul
    Perol, David
    Bachelot, Thomas
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 343 - 350
12345